ADC Therapeutics SA
NYSE:ADCT

ADC Therapeutics SA (NYSE:ADCT)

Add ADCT to Watchlist

Income Statement

16.9M
Revenue
1 Year
N/A
3 Years
N/A
5 Years
N/A
16.3M
Gross Proft
1 Year
N/A
3 Years
N/A
5 Years
N/A
-276.9M
Operating Income
1 Year
N/A
3 Years
N/A
5 Years
N/A
-251.6M
Net Income
1 Year
N/A
3 Years
N/A
5 Years
N/A
Currency: USD
Sep-2021 Jun-2021 Mar-2021 Dec-2020
Revenue
Revenue
17
+350%
4
-
0
-
0
-
Gross Profit
Cost of Revenue
(1)
(0)
0
0
Gross Profit
16
+347%
4
-
0
-
0
-
Operating Income
Operating Expenses
(293)
(268)
(246)
(219)
Selling, General & Administrative
(129)
(116)
(100)
(77)
Research & Development
(157)
(152)
(146)
(142)
Depreciation & Amortization
0
(0)
0
0
Other Operating Expenses
(7)
0
0
0
Operating Income
(277)
-5%
(265)
-8%
(246)
-12%
(219)
-
Pre-Tax Income
Interest Income Expense
26
71
(9)
(27)
Non-Reccuring Items
0
(7)
0
0
Total Other Income
0
1
1
1
Pre-Tax Income
(251)
-26%
(200)
+21%
(254)
-3%
(246)
-
Net Income
Tax Provision
(1)
(0)
(0)
(0)
Income from Continuing Operations
(252)
(200)
(254)
(246)
Net Income (Common)
(252)
-26%
(200)
+21%
(254)
-3%
(246)
-

Balance Sheet

638M
Assets
1 Year
22%
3 Years
N/A
5 Years
N/A
451M
Liabilities
1 Year
210%
3 Years
N/A
5 Years
N/A
187M
Equity
1 Year
-50%
3 Years
N/A
5 Years
N/A
Currency: USD
Sep-2021 Jun-2021 Mar-2021 Dec-2020 Sep-2020 Jun-2020 Dec-2019 Jun-2019
Assets
Cash & Cash Equivalents
530
372
383
439
494
349
116
182
Cash Equivalents
530
372
383
439
494
349
116
182
Total Receivables
16
2
0
0
0
0
0
0
Accounts Receivables
16
2
0
0
0
0
0
0
Other Receivables
0
0
0
0
0
0
0
0
Inventory
8
8
0
0
0
0
0
0
Other Current Assets
14
13
10
11
12
11
7
3
Total Current Assets
568
394
393
451
506
359
123
185
PP&E Net
12
11
11
5
5
6
6
7
PP&E Gross
0
11
0
0
0
0
0
0
Accumulated Depreciation
0
2
0
0
0
0
0
0
Intangible Assets
13
12
10
10
10
9
8
8
Long-Term Investments
44
46
47
48
0
0
0
0
Other Long-Term Assets
1
0
0
0
0
0
0
0
Total Assets
638
+37%
464
+1%
462
-10%
514
-1%
522
+40%
374
+171%
138
-31%
201
-
Liabilities
Accounts Payable
12
15
12
5
6
7
3
1
Short-Term Debt
0
0
0
0
0
0
0
0
Current Portion of Long-Term Debt
8
7
4
5
4
4
1
1
Other Current Liabilities
40
30
26
31
23
20
16
15
Total Current Liabilities
59
51
41
40
33
31
20
17
Long-Term Debt
308
92
43
37
36
36
4
4
Other Liabilities
84
77
79
101
77
110
3
2
Total Liabilities
451
+104%
220
+35%
164
-8%
178
+22%
146
-18%
178
+570%
27
+16%
23
-
Equity
Common Stock
6
6
6
6
6
6
4
0
Retained Earnings
801
744
690
652
611
602
443
376
Additional Paid In Capital
982
981
981
981
981
793
550
527
Treasury Stock
0
0
0
0
0
0
0
0
Other Equity
0
0
0
0
0
0
0
27
Total Equity
187
-23%
244
-18%
298
-11%
336
-11%
376
+92%
196
+77%
111
-38%
178
-
Total Liabilities & Equity
638
+37%
464
+1%
462
-10%
514
-1%
522
+40%
374
+171%
138
-31%
201
-
Shares Outstanding
Common Shares Outstanding
76.7M
76.7M
76.7M
76.7M
76.7M
70.7M
76.7M
73.3M

Cash Flow Statement

-209.2M
Operating Cash Flow
1 Year
-51%
3 Years
N/A
5 Years
N/A
-5.7M
Capital Expenditures
1 Year
-553%
3 Years
N/A
5 Years
N/A
-214.9M
Free Cash Flow
1 Year
-54%
3 Years
N/A
5 Years
N/A
Currency: USD
Jun-2021 Mar-2021 Dec-2020 Sep-2020 Jun-2020 Dec-2019
Operating Cash Flow
Net Income
(200)
(298)
(246)
(257)
(237)
(116)
Depreciation & Amortization
2
3
2
2
2
2
Other Non-Cash Items
(19)
59
64
71
92
0
Cash Taxes Paid
0
(0)
0
0
0
0
Cash Interest Paid
4
3
2
2
0
0
Change in Working Capital
7
12
12
1
4
(7)
Cash from Operating Activities
(209)
+7%
(224)
-33%
(169)
+8%
(183)
-32%
(139)
-14%
(122)
-
Investing Cash Flow
Capital Expenditures
(6)
(3)
(3)
(2)
(1)
(2)
Other Items
0
(0)
(0)
0
0
(0)
Cash from Investing Activities
(6)
-63%
(3)
-23%
(3)
-19%
(2)
-145%
(1)
+57%
(2)
-
Financing Cash Flow
Net Issuance of Common Stock
189
433
433
436
244
102
Net Issuance of Debt
49
61
62
62
62
(1)
Cash from Financing Activities
238
-52%
495
0%
495
0%
497
+63%
306
+205%
101
-
Change in Cash
Effect of Foreign Exchange Rates
0
0
0
0
(0)
0
Net Change in Cash
23
-91%
268
-17%
324
+4%
312
+88%
166
-
(23)
-